For the first time since the launch debacle of Clozapine REMS in the fall of 2015 a representative at the call center admitted to me in a call this morning that she works for (presumably a division of) McKesson Pharmaceuticals. Now, will the FDA hold McKesson accountable for the problems we have encountered in the administration of the program?
I had called Clozapine REMS to inform them that they had mistakenly sent me a notice that a former patient no longer under my care is overdue for the required blood test.
I left a message with FDA to report this apparent communication breakdown. I will report in a future post how (or whether) FDA responds.
I hope the call center representative did not just slip up, and that her admission represents change to a policy of increased openness.